查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肝細胞癌症市場:KOL的洞察
市場調查報告書
商品編碼
1770211

肝細胞癌症市場:KOL的洞察

KOL Insight - Hepatocellular Carcinoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入分析了肝細胞癌 (HCC) 市場中現有及新興的生物製劑和研發管線療法。報告基於12位關鍵意見領袖的洞察，探討了卡博替尼 (Cabometyx) 和 Styvarga 使用率的下降、賽默飛世爾 (Cyramza) 的微弱影響以及 Tebinbra/Tizveni 預計帶來的有限影響。報告中也探討了 Tecentriq + Avastin 合併療法、Imfinzi + Imjudo 的用法，以及近期臨床試驗對 HCC 治療模式的影響。您將全面了解影響治療偏好的因素、新療法面臨的課題以及不斷發展的治療方案。

關鍵問題解答

  • KOL 如何使用 Tecentriq + Avastin 治療 HCC？
  • IMbrave050 的數據是否改變了 Tecentriq 的輔助治療？
  • Imfinzi + Imjudo 組合在目前的治療方案中處於什麼位置？
  • KOL 如何看待 Opdivo + Yervoy 在肝細胞癌第一線治療中的作用？
  • 專家如何看待 LEAP-012 和 CheckMate-9DW 研究的結果？
  • IMbrave251 與 EMERALD-2 等研究如何塑造治療格局？
  • KOL 目前如何使用 Lenvima、Stivarga、Cabometyx 和 Cyramza？
  • 專家對哪些在研肝細胞癌療法最為期待？

領導品牌

  • TECENTRIQ(Atezolizumab)
  • Avastin(Bevacizumab)
  • imufinji(Durvalumab)
  • imujudo(Tremelimumab)
  • Opdivo(Nivolumab)
  • yaboi(Ipilimumab)
  • KEYTRUDA(Pembrolizumab)
  • LENVIMA(Lenvatinib)
  • suchibaga(Regorafenib)
  • 卡博替尼（卡博替尼）
  • 賽樂姆（雷莫蘆單抗）
  • 替舒利珠單抗
  • 納莫德諾松
  • 替拉戈單抗
  • 利莫尼利單抗
  • 布地加利單抗
  • 卡舒吉特舒格
  • 阿米札魯胺

參加專家清單的一部分

  • 德州大學西南醫學中心肝腫瘤學程主任、教授、肝病學負責人
  • 美國密西根州多學科肝腫瘤診所主任、助理教授、活體肝臟移植醫療主任、移植計畫負責人
  • 胃腸病學和肝病學系助理教授史丹佛大學醫學院，加州
  • 西班牙巴塞隆納大學巴塞隆納診所醫院 ICMDM、IDIBAPS 巴塞隆納診所肝癌 (BCLC) 組肝病科肝病專家
  • 英國倫敦帝國學院外科和腫瘤學系臨床科學家兼腫瘤顧問醫生
  • 義大利博洛尼亞大學醫學與外科教授

方法論

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，就關鍵疾病領域的當前和未來治療前景進行深入探討。 KOL 是根據嚴格的篩選標準精心挑選出來的，這些標準包括全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都附有精心設計的討論指南。這些指南由我們與 KOL 合作制定，並由行業專家進行同行評審，以確保所提出的問題全面且與當前市場動態相關。透過在每份報告發布後12個月的持續市場監測，我們及時為您提供來自關鍵意見領袖 (KOL) 的重要新聞事件、市場變化和市場發展動態的更新。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且切實可行的洞察。我們深厚的行業知識使我們能夠為您提供相關且有價值的洞察，幫助您掌握新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告可提供您所需的準確性和可靠性。獨家訪問獨家訪談和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策，從而在快速變化的行業中保持競爭力。

簡介目錄

This report provides a detailed analysis of current and emerging biologic and pipeline therapies in the hepatocellular carcinoma (HCC) market. Based on insights from 12 key opinion leaders, it examines the declining use of Cabometyx and Stivarga, the minimal impact of Cyramza, and the limited disruption expected from Tevimbra/Tizveni. The report also explores the use of Tecentriq plus Avastin, the uptake of Imfinzi and Imjudo, and the implications of recent clinical trials on the HCC treatment paradigm. Gain a comprehensive understanding of the factors influencing treatment preferences, the challenges new therapies face, and the evolving treatment algorithms.

Key Questions Answered:

  • How do KOLs use Tecentriq plus Avastin in HCC treatment?
  • Has the IMbrave050 data changed Tecentriq's adjuvant use?
  • Where does Imfinzi plus Imjudo fit in the current treatment algorithm?
  • How do KOLs view Opdivo plus Yervoy for first-line HCC?
  • What is the expert take on LEAP-012 and CheckMate -9DW trial results?
  • How are trials like IMbrave251 and EMERALD-2 shaping the landscape?
  • How do KOLs use Lenvima, Stivarga, Cabometyx and Cyramza today?
  • Which pipeline therapies excite experts the most for HCC?

Key Brands:

  • Tecentriq (atezolizumab)
  • Avastin (bevacizumab)
  • Imfinzi (durvalumab)
  • Imjudo (tremelimumab)
  • Opdivo (nivolumab)
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)
  • Lenvima (lenvatinib)
  • Stivarga (regorafenib)
  • Cabometyx (cabozantinib)
  • Cyramza (ramucirumab)
  • tislelizumab
  • namodenoson
  • tiragolumab
  • livmoniplimab
  • budigalimab
  • casdozokitug
  • amezalpat

Partial List of Participating Experts:

  • Professor, Medical Director of the Liver Tumor Program and Chief of Hepatology, University of Texas Southwestern Medical Center, TX
  • Assistant Professor, Medical Director of the Multidisciplinary Liver Tumor Clinic and Medical Director of the Living Donor Liver Transplantation Program, Michigan, US
  • Assistant Professor in the Division of Gastroenterology and Hepatology at the School of Medicine, Stanford University, CA
  • Hepatologist at the Liver Unit, Barcelona Clinic Liver Cancer (BCLC) group, ICMDM, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
  • Clinician Scientist and Consultant Medical Oncologist, Department of Surgery and Cancer, Imperial College London, London, UK
  • Full Professor, Department of Medical and Surgical Sciences, University of Bologna, Italy

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.